Catastrophic antiphospholipid syndrome: Treatment, prognosis, and the risk of relapse

Clinical Reviews in Allergy and Immunology

Volumn 36, Issue 2-3, 2009, Pages 80-84

  Bucciarelli, Silvia ^a   Erkan, Doruk ^b   Espinosa, Gerard ^a   Cervera, Ricard ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b Department of Obstetrics Gynecology   (United States)

Author keywords

Anticoagulation; Antiphospholipid syndrome; Corticosteroids; Intravenous immunoglobulins; Plasma exchange

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; FRESH FROZEN PLASMA; HEPARIN; IMMUNOGLOBULIN; RITUXIMAB; MONOCLONAL ANTIBODY;

ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; AUTOPSY; CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME; HUMAN; PLASMAPHERESIS; PROGNOSIS; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; AGE; BACTERIAL INFECTION; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; MULTIPLE ORGAN FAILURE; PATHOPHYSIOLOGY; RECURRENT DISEASE; RISK FACTOR; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; AGE FACTORS; ANTIBODIES, MONOCLONAL; ANTIPHOSPHOLIPID SYNDROME; BACTERIAL INFECTIONS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSION; LUPUS ERYTHEMATOSUS, SYSTEMIC; MULTIPLE ORGAN FAILURE; PLASMAPHERESIS; PROGNOSIS; RECURRENCE; RISK FACTORS; TREATMENT OUTCOME;

EID: 66349107412     PISSN: 10800549     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12016-008-8107-9     Document Type: Review

References (39)

1. RA Asherson 1992 The catastrophic antiphospholipid syndrome J Rheumatol 19 508 512
2. R Cervera JC Piette J Font MA Khamashta Y Shoenfeld MT Camps et al. 2002 Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients Arthritis Rheum 46 1019 1027
3. RA Asherson R Cervera JC Piette J Font JT Lie A Burcoglu et al. 1998 Catastrophic antiphospholipid syndrome: clinical and laboratory features of 50 patients Medicine (Baltimore) 77 195 207
4. RA Asherson R Cervera JC Piette Y Shoenfeld G Espinosa MA Petri et al. 2001 Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients Medicine (Baltimore) 80 355 376
5. RA Asherson R Cervera PR de Groot D Erkan MC Boffa JC Piette et al. 2003 Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines Lupus 12 530 534
6. S Bucciarelli G Espinosa R Cervera D Erkan JA Gómez-Puerta M Ramos-Casals et al. 2006 Mortality in catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients Arthritis Rheum 54 2568 2576
7. G Girardi P Redecha JE Salmon 2004 Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation Nat Med 10 1222 1226
8. JW Christman LH Lancaster TS Blackwell 1998 Nuclear factor kappa B: a pivotal role in the systemic inflammatory response syndrome and new target for therapy Intensive Care Med 24 1131 1138
9. I Uthman A Shamseddine A Taher 2005 The role of therapeutic plasma exchange in catastrophic antiphospholipid syndrome Transfus Apher Sci 33 11 17
10. D Erkan R Cervera RA Asherson 2003 Catastrophic antiphospholipid syndrome: where do we stand Arthritis Rheum 48 3320 3327
11. H Orbach U Katz Y Sherer Y Shoenfeld 2005 Intravenous immunoglobulin: adverse effects and safe administration Clin Rev Allergy Immunol 29 173 184
12. UD Bayraktar D Erkan S Bucciarelli G Espinosa RA Asherson Catastrophic Antiphospholipid Syndrome Project Group 2007 The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupus J Rheumatol 34 346 352
13. R Tenedious D Erkan MD Lockshin 2005 Rituximab in the primary antiphospholipid syndrome Arthritis Rheum 52 4078
14. JG Erdozain G Ruiz-Irastorza MV Egurbide et al. 2004 Sustained response to rituximab of autoimmune hemolytic anemia associated with antiphospholipid syndrome Haematologica 89 ECR34
15. E Rubenstein DG Arkfeld S Metyas S Shinada S Ehresmann HA Liebman 2006 Rituximab treatment for resistant antiphospholipid syndrome J Rheumatol 33 355 357
16. Yamazaki et al. 2004 Rituximab decreases antiphospholipid antibody titers and improves hypercoagulable state without recurrent thrombosis: 2-year follow-up Thromb Res 114 610
17. Tommasino et al. 2004 Short-term lack of efficacy of rituximab in a thrombocytopaenic patient with primary antiphospholipid syndrome Thromb Res 114 652
18. S Vero RA Asherson D Erkan 2006 Critical care review: Catastrophic antiphospholipid syndrome J Intens Care Med 21 144 159
19. D Erkan RA Asherson G Espinosa et al. 2003 Long term outcome of catastrophic antiphospholipid síndrome survivors Ann Rheum Dis 62 530 533
20. R Asherson G Espinosa S Menahen et al. 2008 Relapsing catastrophic antiphsopholipid syndrome: Report of three cases Semin Arthritis Rheum 37 366 372
21. JJ Murphy IH Leach 1989 Finding at necropsy in the heart of a patient with anticardiolipin syndrome Br Heart J 62 61 64
22. CM Neuwelt DI Daikh JA Linfoot et al. 1997 Catastrophic antiphospholipid syndrome. Responce to repetead plasmapheresis over three years Arthritis Rheum 40 1534 1539
23. A Undas J Swadzba R Undas J Musial 1998 Three episodes of acute multiorgan failure in a woman with secondary antiphospholipid syndrome Pol Arch Med Wewn 100 556 560
24. K Cerveny AD Sawitzke 1999 Relapsing catastrophic antiphsopholipid antibody syndrome: a mimic for thrombotic thrombocytopenic purpura Lupus 8 477 481
25. A Gordon CA McLean P Ryan SK Roberts 2004 Steroids responsive catastrophic antiphospholipid syndrome J Gastroenterol Hepatol 19 479 480
26. MS Willis N Bandarenko 2005 Relapse of thrombotic thrombocytopenic purpura: is it a continuum of diseases Semin Throm Haemost 31 700 708
27. PL Meroni 2008 Pathogenesis of the antiphospholipid syndrome: an additional example of the mosaic of autoimmunity J Autoimmun 30 99 103
28. L Andreoli F Pregnolato RW Burlingame F Allegri S Rizzini V Fanelli A Radice C Corace RA Sinico PL Meroni A Tincani 2008 Antinucleosome antibodies in primary antiphospholipid syndrome: a hint at systemic autoimmunity J Autoimmun 30 51 57
29. Y Shoenfeld G Twig U Katz Y Sherer 2008 Autoantibody explosion in antiphospholipid syndrome J Autoimmun 30 74 83
30. T Kajiwara T Yasuda E Matsuura 2007 Intracellular trafficking of beta2-glycoprotein I complexes with lipid vesicles in macrophages: implications on the development of antiphospholipid syndrome J Autoimmun 29 164 173
31. I Cavazzana N Manuela C Irene A Barbara S Sara BM Orietta T Angela T Francesco MP Luigi 2007 Complement activation in anti-phospholipid syndrome: a clue for an inflammatory process J Autoimmun 28 160 164
32. T Koike M Bohgaki O Amengual T Atsumi 2007 Antiphospholipid antibodies: lessons from the bench J Autoimmun 28 129 133
33. PL Meroni Y Shoenfeld 2008 Predictive, protective, orphan autoantibodies: the example of anti-phospholipid antibodies Autoimmun Rev 7 585 587
34. HM Cheng L Chamley 2008 Cryptic natural autoantibodies and co-potentiators Autoimmun Rev 7 431 434
35. M Frank M Mancek-Keber M Krzan S Sodin-Semrl R Jerala A Iglic B Rozman V Kralj-Iglic 2008 Prevention of microvesiculation by adhesion of buds to the mother cell membrane-a possible anticoagulant effect of healthy donor plasmma Autoimmun Rev 7 240 245
36. R Cervera 2008 Lessons from the "Euro-Phospholipid" project Autoimmun Rev 7 174 178
37. S Sodin-Semrl B Rozman 2007 Beta2-glcyoprotein I and its clinical significance: from gene sequence to protein levels Autoimmun Rev 6 547 552
38. M Bagnasco L Grassia G Pesce 2007 The management of the patient with unexpected autoantibody positivity Autoimmun Rev 6 347 353
39. E Muscal BL Myones 2007 The role of autoantibodies in pediatric neuropsychiatric systemic lupus erythematosus Autoimmun Rev 6 215 217